Mr. Hugh MacNaught reports

VENTRIPOINT WELCOMES MATT DOBSON AS MARKETING DIRECTOR TO GUIDE MARKET DEVELOPMENT AND PRODUCT MANAGEMENT

Ventripoint Diagnostics Ltd. has appointed Matt Dobson as the company's new marketing director, to accelerate the company's path to commercialization.

A seasoned professional in strategic marketing, Mr. Dobson brings a wealth of experience from his tenure in various marketing roles and industries, including medical technology, diagnostics, therapeutics, technology and fast-paced consumer goods.

Based in the United Kingdom, Mr. Dobson will focus on developing actionable product development, marketing and sales programs built upon proprietary market, customer and user insights and ensuring optimal product-customer fit.

"Matt has excelled in past assignments and will be key in evolving Ventripoint to becoming a market-driven organization," said Ventripoint's chief executive officer, Hugh MacNaught. "Our focus is developing actionable insights on how to drive adoption of Ventripoint's technology in routine clinical practice."

Added Mr. Dobson: "Ventripoint's proposition is unique, offering a revolutionary mix of accuracy, efficiency and user-friendliness in cardiac imaging using artificial intelligence. This affordable tool promises to advance heart health management, making heart scans with cMRI levels of accuracy available to more people, at a fraction of the cost and with results in minutes."

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to magnetic resonance imaging. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all Ventripoint's products that guide its future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

We seek Safe Harbor.